Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry.
about
Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.Pharmacokinetics of LJP 993, a tetrameric conjugate of domain 1 of beta2-glycoprotein I for antiphospholipid syndromePharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken designEnhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study.Nanosuspension: An approach to enhance solubility of drugsFabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability.The performance of nanocarriers for transmucosal drug delivery.Biopharmaceutics and therapeutic potential of engineered nanomaterials.Oral formulation of a novel antiviral agent, PG301029, in a mixture of gelucire 44/14 and DMA (2:1, wt/wt).Controlled delivery systems: from pharmaceuticals to cells and genes.Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids.Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds.AIDS treatment with novel anti-HIV compounds improved by nanotechnologyA potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation.Comparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model.Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite).Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development.A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development.
P2860
Q30903645-011A6E5F-735B-4A12-AD49-8A7F68D66FB7Q33698159-0EC38E47-DB1C-4645-98D7-B8D86FC5FF57Q34383718-0E4EA257-1BAE-48B4-B74E-6A0B33F3E7F1Q35024394-0A0E0299-BCA8-4583-9657-32D5CA2216DBQ35185309-C02F8419-E9A3-4D1D-9D4E-38160623FA34Q35554511-7BF3D3F8-C5E6-45EF-9536-563DF442E93AQ35580982-4A5D8872-6A96-4C3F-A850-8DAFFA661453Q36527739-8AA562D6-B48E-4AFE-BE3D-2A05785138F0Q37273411-54CA9D45-2215-4F0F-8927-E1D8EB73E070Q37360661-785E964D-55D5-42B6-8A1C-385411676779Q37855597-3DBDDDB9-AE56-405A-B653-5FDC89E1EA97Q37967163-E42F2900-7684-4C47-8C47-D599865237BFQ38021953-650ED821-20F9-4B1A-8EFB-77DA76FDF76BQ42739576-B74B44E6-FCAC-4CA5-A982-3F0C8659AAD5Q43866758-2A8CC80B-6FC9-44A7-8882-8D626829A138Q46113649-4F65F1C9-01ED-42CB-986A-8589D007E952Q47133712-B7BE7BFC-B5F1-4CFF-ABD7-713059BB1BF2Q47405828-DC596C21-140E-4655-ADC8-226BB342DB41Q47422612-03A486AE-A62E-4E5C-AFEA-41F2BFBB4EF0
P2860
Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Effect of nanonization on abso ...... omatography/mass spectrometry.
@ast
Effect of nanonization on abso ...... omatography/mass spectrometry.
@en
type
label
Effect of nanonization on abso ...... omatography/mass spectrometry.
@ast
Effect of nanonization on abso ...... omatography/mass spectrometry.
@en
prefLabel
Effect of nanonization on abso ...... omatography/mass spectrometry.
@ast
Effect of nanonization on abso ...... omatography/mass spectrometry.
@en
P2093
P356
P1476
Effect of nanonization on abso ...... omatography/mass spectrometry.
@en
P2093
Cesario Cerna
Steve D Weitman
P304
P356
10.1023/A:1019829622088
P50
P577
2002-08-01T00:00:00Z